Skip to content

Comparing efficacy of two treatment methods including topical liposomal Amphotericin B versus intralesional Meglumine Antimoniate (Glucantime) in the Treatment of Cutaneous Leishmaniasis

Efficacy of Topical Liposomal Amphotericin B versus Intralesional Meglumine Antimoniate (Glucantime) in the Treatment of Cutaneous Leishmaniasis

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT138802131871N1
Enrollment
110
Registered
2009-09-26
Start date
2004-09-10
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cutaneous leishmaniasis. Cutaneous Leishmaniasis

Interventions

Intervention 1: Multilamellar Large Vesicle (MLV) liposomes containing Amphotricin B, prepared by freeze drying method, 3-7 drops twice-daily, according to the lesion's size for 8 weeks or complete he
Treatment - Drugs
Multilamellar Large Vesicle (MLV) liposomes containing Amphotricin B, prepared by freeze drying method, 3-7 drops twice-daily, according to the lesion's size for 8 weeks or complete healing of the les
Intralesional glucantime (Specia®, France) once a week, to the point when the lesion’s surface became fully infiltrated, up to a maximum dose of 2 ml for 8 weeks

Sponsors

Research Council of Mashhad University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
2 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Presence of cutaneous leishmaniasis approved by either a direct smear stained with Giemsa or a positive skin biopsy of lesions with less than 6 months duration, in cases of previous history of anti-leishmania therapy, a 3 month treatment free interval from the last treatment course Exclusion criteria: Pregnancy, breast feeding, taking any other specific treatment while participating in the study, past medical history of any local or systemic disease during the last 2 months, presence of significant underlying disease such as cardiac, renal or liver dysfunction

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Complete healing. Timepoint: First time within 8 weeks after beginning of treatment and second one after 6 months after initiation of the intervention(s). Method of measurement: Measuring the size of induration and ulcer.

Secondary

MeasureTime frame
Adverse Effects. Timepoint: Recorded at each follow-up visit. Method of measurement: Taking medical history and performing physical examination.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Pouran Layegh

Department of Dermatology, Qaem Hospital, Mashad University of Medical Sciences

layeghpo@mums.ac.ir+98 51 1881 4988

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026